Uncategorized

Amylyx eyes FDA filing for GLP-1 blocker after late-stage win in post-bariatric hypoglycemia

Published

on

With a Phase 3 trial reducing serious and severe hypoglycemic episodes following weight loss surgery, Amylyx Pharmaceuticals plans to file for approval this year. If granted market entry, avexitide could hit peak sales of $1.7 billion worldwide, analysts estimate.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version